Australian Financial Review Journalist, Bina Brown reported on an Australian equities market shift away from resources into biotech and included Starpharma as a company to watch. The article noted the recent positive data showing that the Company’s delivery technology can make commonly use cancer drugs work a lot better as well as reduce side effects that can result in patients having to stop treatment.

 “[Starpharma’s] delivery technology can not only make commonly used cancer drugs work a lot better, but can get rid of the main side-effects that can mean cancer patients have to stop using them.. ‘If the human data is anything like what we have seen in preclinical ­studies, this will be a total game changer.’”

Starpharma today announced the selection of Mr Robert Thomas for appointment to the Board as a non-executive director.  He will be appointed in December 2013 and will assume the role of Chairman mid-year when Mr Peter Bartels retires as part of a deliberate succession plan and board renewal.

Starpharma today released its Appendix 4C – Quarterly Cashflow report for the period ended 30 September 2013.

The cash balance at 30 September 2013 was $31.5 million, a net cash burn of $2.3 million for the quarter.

Starpharma today announced additional positive results for its dendrimer formulation of the major chemotherapeutic, docetaxel (Taxotere^®), ahead of its advancement into clinical trials later this year.

ABC News’ The Business Presenter Ticky Fullerton interviewed Starpharma CEO Dr Jackie Fairley on Wednesday 16^th October 2013. Ticky discussed the positive results of Starpharma’s dendrimer version of oxaliplatin.

 Watch the video (external link)

Starpharma CEO Dr Jackie Fairley joined Sky News to discuss the positive results of the Company’s pre-clinical trial of Dendrimer-Enhanced Oxaliplatin. Starpharma’s dendrimer version of the blockbuster colon and colorectal cancer drug was shown to be less neurotoxic than conventional oxaliplatin.

View the Interview

Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced further positive results for its Dendrimer-Enhanced Oxaliplatin (DEO), specifically that its dendrimer version of oxaliplatin results in a significant reduction in the serious neurotoxicity commonly seen with oxaliplatin. 

Starpharma Holdings Ltd (ASX:SPL; OTCQX:SPHRY) and Gowan Company LLC today announced a new partnership using Starpharma’s Priostar^® dendrimer technology in crop protection formulations.

Under the agreement, Starpharma’s Priostar^® dendrimers will be evaluated as potential enhancements for certain Gowan products intended for high value markets.

Melbourne, Australia: Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced it had achieved improved tumour-inhibiting efficacy and reduced overall toxicity using a dendrimer enhanced version of the blockbuster cancer drug, oxaliplatin (ELOXATIN®).

These positive results were demonstrated in a pre-clinical study, which examined dendrimer-enhanced nanoparticle versions of oxaliplatin compared with ELOXATIN® (oxaliplatin) in a colon cancer model (xenograft).